<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28356282</article-id><article-id pub-id-type="pmc">5533039</article-id><article-id pub-id-type="doi">10.1161/JAHA.117.005650</article-id><article-id pub-id-type="publisher-id">JAH32122</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Interventional Cardiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin&#x02010;Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention</article-title><alt-title alt-title-type="left-running-head">Sweeny et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32122-cr-0001" contrib-type="author" corresp="yes"><name><surname>Sweeny</surname><given-names>Joseph M.</given-names></name><degrees>MD</degrees><address><email>joseph.sweeny@mountsinai.org</email></address><xref ref-type="aff" rid="jah32122-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32122-cr-0002" contrib-type="author"><name><surname>Angiolillo</surname><given-names>Dominick J.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32122-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32122-cr-0003" contrib-type="author"><name><surname>Franchi</surname><given-names>Francesco</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32122-cr-0004" contrib-type="author"><name><surname>Rollini</surname><given-names>Fabiana</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32122-cr-0005" contrib-type="author"><name><surname>Waksman</surname><given-names>Ron</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32122-cr-0006" contrib-type="author"><name><surname>Raveendran</surname><given-names>Ganesh</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32122-cr-0007" contrib-type="author"><name><surname>Dangas</surname><given-names>George</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32122-cr-0008" contrib-type="author"><name><surname>Khan</surname><given-names>Naeem D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32122-cr-0009" contrib-type="author"><name><surname>Carlson</surname><given-names>Glenn F.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32122-cr-0010" contrib-type="author"><name><surname>Zhao</surname><given-names>Yonggang</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32122-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32122-cr-0011" contrib-type="author"><name><surname>Teng</surname><given-names>Renli</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32122-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32122-cr-0012" contrib-type="author"><name><surname>Mehran</surname><given-names>Roxana</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32122-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah32122-aff-0001">
<label><sup>1</sup></label>
<institution>Icahn School of Medicine at Mount Sinai</institution>
<named-content content-type="city">New York</named-content>
<named-content content-type="country-part">NY</named-content>
</aff><aff id="jah32122-aff-0002">
<label><sup>2</sup></label>
<institution>University of Florida College of Medicine&#x02010;Jacksonville</institution>
<named-content content-type="city">Jacksonville</named-content>
<named-content content-type="country-part">FL</named-content>
</aff><aff id="jah32122-aff-0003">
<label><sup>3</sup></label>
<institution>MedStar Washington Hospital Center</institution>
<named-content content-type="city">Washington</named-content>
<named-content content-type="country-part">DC</named-content>
</aff><aff id="jah32122-aff-0004">
<label><sup>4</sup></label>
<institution>University of Minnesota Medical School</institution>
<named-content content-type="city">Minneapolis</named-content>
<named-content content-type="country-part">MN</named-content>
</aff><aff id="jah32122-aff-0005">
<label><sup>5</sup></label>
<institution>AstraZeneca</institution>
<named-content content-type="city">Wilmington</named-content>
<named-content content-type="country-part">DE</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Joseph M. Sweeny, MD, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, One Gustave L. Levy Place, Box&#x000a0;1030, New York, NY 10029&#x02010;6574. E&#x02010;mail: <email>joseph.sweeny@mountsinai.org</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2017</year></pub-date><volume>6</volume><issue>4</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-4</issue-id><elocation-id>e005650</elocation-id><history><date date-type="received"><day>25</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors and AstraZeneca. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e005650.pdf"/><abstract id="jah32122-abs-0001"><sec id="jah32122-sec-0001"><title>Background</title><p>Diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) is associated with enhanced platelet reactivity and impaired response to oral antiplatelet therapy, including clopidogrel. This post hoc analysis investigated the pharmacodynamic effects of ticagrelor versus clopidogrel loading dose (<styled-content style="fixed-case">LD</styled-content>) in troponin&#x02010;negative acute coronary syndrome patients with or without <styled-content style="fixed-case">DM</styled-content> undergoing percutaneous coronary intervention in the Ad Hoc <styled-content style="fixed-case">PCI</styled-content> study.</p></sec><sec id="jah32122-sec-0002"><title>Methods and Results</title><p>Patients randomized (1:1) to receive ticagrelor 180&#x000a0;mg <styled-content style="fixed-case">LD</styled-content> or clopidogrel 600&#x000a0;mg <styled-content style="fixed-case">LD</styled-content> were assessed by diabetic status. Platelet reactivity (P2Y<sub>12</sub> reaction units [<styled-content style="fixed-case">PRU</styled-content>] on VerifyNow<sup>&#x000ae;</sup> assay) was measured pre&#x02010;<styled-content style="fixed-case">LD</styled-content>, at 0.5, 2, and 8&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content>, and at the end of the percutaneous coronary intervention. The primary endpoint was <styled-content style="fixed-case">PRU</styled-content> levels 2&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content>; secondary endpoints included rates of high on&#x02010;treatment platelet reactivity (<styled-content style="fixed-case">PRU</styled-content>&#x02265;208). Of 100 randomized patients, 51 received ticagrelor (<styled-content style="fixed-case">DM</styled-content>, n=20; non&#x02010;<styled-content style="fixed-case">DM</styled-content>, n=31) and 49 clopidogrel (<styled-content style="fixed-case">DM</styled-content>, n=16; non&#x02010;<styled-content style="fixed-case">DM</styled-content>, n=33). At 2&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content>, mean (<styled-content style="fixed-case">SD</styled-content>) <styled-content style="fixed-case">PRU</styled-content> levels in <styled-content style="fixed-case">DM</styled-content> patients were 130.1 (111.7) with ticagrelor versus 287.6 (71.9) with clopidogrel (mean [95%<styled-content style="fixed-case">CI</styled-content>] difference &#x02212;157.5 [&#x02212;225.3, &#x02212;89.8]; <italic>P</italic>&#x0003c;0.001); in non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients, they were 75.3 (75.7) versus 243.0 (72.4) (mean difference &#x02212;167.7 [&#x02212;207.1, &#x02212;128.3]; <italic>P</italic>&#x0003c;0.001). High on&#x02010;treatment platelet reactivity rates at 2&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content> were also significantly (<italic>P</italic>&#x0003c;0.001) reduced with ticagrelor versus clopidogrel in <styled-content style="fixed-case">DM</styled-content> and non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients. Between&#x02010;treatment differences for <styled-content style="fixed-case">PRU</styled-content> and high on&#x02010;treatment platelet reactivity were not significant at earlier time points but were at 8&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content> (<italic>P</italic>&#x0003c;0.001).</p></sec><sec id="jah32122-sec-0003"><title>Conclusions</title><p>Compared with clopidogrel, ticagrelor achieved faster, enhanced platelet inhibition and reduced high on&#x02010;treatment platelet reactivity rates, in <styled-content style="fixed-case">DM</styled-content> and non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients.</p></sec><sec id="jah32122-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>01603082.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32122-kwd-0001">ad hoc percutaneous coronary intervention</kwd><kwd id="jah32122-kwd-0002">clopidogrel</kwd><kwd id="jah32122-kwd-0003">diabetes mellitus</kwd><kwd id="jah32122-kwd-0004">platelet reactivity</kwd><kwd id="jah32122-kwd-0005">ticagrelor</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Percutaneous Coronary Intervention</kwd><kwd>Treatment</kwd></kwd-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="10"/><word-count count="6392"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32122</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.3 mode:remove_FC converted:11.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32122-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005650</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.005650">10.1161/JAHA.117.005650</ext-link>.)<pub-id pub-id-type="pmid">28356282</pub-id></mixed-citation>
</p></notes></front><body><sec id="jah32122-sec-0005"><title>Introduction</title><p>Diabetes mellitus (DM) is associated with a high risk of recurrent cardiovascular events.<xref rid="jah32122-bib-0001" ref-type="ref">1</xref> Compared with non&#x02010;DM patients, those with DM (particularly type 2) have greater atheromatous plaque burden<xref rid="jah32122-bib-0002" ref-type="ref">2</xref> and also an increased tendency to activate and aggregate platelets despite antiplatelet therapy.<xref rid="jah32122-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32122-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32122-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32122-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32122-bib-0007" ref-type="ref">7</xref> In particular, studies have consistently shown that DM patients have impaired clopidogrel&#x02010;induced antiplatelet effects, leading to high on&#x02010;treatment platelet reactivity (HPR).<xref rid="jah32122-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32122-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32122-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32122-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32122-bib-0007" ref-type="ref">7</xref> Importantly, HPR is a well&#x02010;established marker of recurrent ischemic events, including stent thrombosis, and may thus contribute to the high event rates observed in DM patients undergoing percutaneous coronary intervention (PCI).<xref rid="jah32122-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32122-bib-0009" ref-type="ref">9</xref> These observations underscore the need for more potent platelet&#x02010;inhibiting therapies in DM patients, particularly among those undergoing PCI.</p><p>Ticagrelor is an oral, direct&#x02010;acting cyclopentyltriazolopyrimidine antiplatelet agent that binds reversibly to the P2Y<sub>12</sub> receptor and has a more rapid onset and robust antiplatelet effect, with low HPR rates, compared with clopidogrel.<xref rid="jah32122-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32122-bib-0011" ref-type="ref">11</xref> This pharmacodynamic profile is indeed advantageous across the spectrum of patients with acute coronary syndromes, irrespective of management, leading to a reduction in ischemic recurrences, including cardiovascular mortality and stent thrombosis.<xref rid="jah32122-bib-0012" ref-type="ref">12</xref> However, there are relatively few studies evaluating the pharmacodynamic effects of ticagrelor versus clopidogrel in DM patients. The Ad Hoc PCI study investigated the periprocedural pharmacodynamic effects of ticagrelor versus clopidogrel loading dose (LD) in troponin&#x02010;negative acute coronary syndrome (ACS) patients who were not pretreated with a P2Y<sub>12</sub> receptor inhibitor, showing ticagrelor to be associated with prompt (by the end of the PCI procedure) and persistent (up to 8&#x000a0;hours post&#x02010;LD) potent platelet inhibitory effects.<xref rid="jah32122-bib-0013" ref-type="ref">13</xref> The aim of this study was to investigate the pharmacodynamic effects of ticagrelor versus clopidogrel according to diabetic status in the Ad Hoc PCI study.</p></sec><sec id="jah32122-sec-0006"><title>Methods</title><sec id="jah32122-sec-0007"><title>Study Design and Patient Population</title><p>This was a post hoc analysis of the Ad Hoc PCI study, a prospective, open&#x02010;label, randomized, multicenter, parallel&#x02010;group, phase 4 pharmacodynamic study performed at 15 centers in the United States (clinicaltrials.gov identifier: NCT01603082). The study methods and main results, including safety outcomes, have been published previously.<xref rid="jah32122-bib-0013" ref-type="ref">13</xref> Briefly, troponin&#x02010;negative, P2Y<sub>12</sub> inhibitor&#x02010;naive, non&#x02010;ST&#x02010;segment elevation ACS patients (women or men, aged &#x02265;18&#x000a0;years) undergoing ad hoc PCI were randomly assigned (1:1) to treatment with ticagrelor 180&#x000a0;mg LD or clopidogrel 600&#x000a0;mg LD, administered in the catheterization laboratory before starting PCI, on a background of aspirin therapy. Patients assigned to the ticagrelor group received a ticagrelor 90&#x02010;mg maintenance dose 12&#x000a0;hours (&#x000b1;1&#x000a0;hour) after the LD. The clopidogrel maintenance dose was chosen by the investigator for ongoing clinical care.</p><p>The study was blinded throughout the PCI procedure until ~1&#x000a0;hour after sheath removal. The study then became open&#x02010;label for clinical staff, but the pharmacodynamic operator remained blinded to the patient's treatment.</p><p>Platelet reactivity was assessed as P2Y<sub>12</sub> reaction units (PRU) by VerifyNow<sup>&#x000ae;</sup> assay (Accriva Diagnostics, San Diego, CA), measured pre&#x02010;LD, at 0.5, 2, and 8&#x000a0;hours post&#x02010;LD, and at the end of PCI. The primary endpoint was PRU at 2&#x000a0;hours after ticagrelor versus clopidogrel LD, and secondary endpoints included PRU at all other time points, percentage reduction from baseline in PRU, percentage inhibition of platelet aggregation (IPA; measured with VerifyNow<sup>&#x000ae;</sup>), and rates of HPR (defined as PRU&#x02265;208) at all time points.<xref rid="jah32122-bib-0013" ref-type="ref">13</xref>
</p><p>Diabetic status was defined according to medical history as reported by the patient at the time of enrollment. However, randomization was not stratified by diabetic status.</p><p>The study complied with the Declaration of Helsinki, International Conference on Harmonisation/Good Clinical Practice guidelines, and applicable regulatory requirements. Institutional review board approval was obtained, and all patients provided informed consent.</p></sec><sec id="jah32122-sec-0008"><title>Statistical Analysis</title><p>A repeated&#x02010;measures analysis of variance model was used to examine the interaction effect between treatment group and diabetic status and to evaluate the treatment effect within DM and non&#x02010;DM groups across time points for PRU levels. Continuous variables were reported as mean (SD), and categorical variables were reported as frequencies and percentages. Continuous variables were analyzed by using 2&#x02010;sample t test to compare the treatment effect between ticagrelor and clopidogrel groups by diabetic status (DM and non&#x02010;DM) and between DM and non&#x02010;DM within each treatment group at each time point. Categorical variables were analyzed by using the Fisher exact test to compare the treatment effect between ticagrelor and clopidogrel groups by diabetic status.</p><p>The pharmacodynamic population included all patients with pharmacodynamic data and without a major protocol deviation and excluded patients with pre&#x02010;LD PRU &#x0003c;150 but included patients with a missing predose PRU measurement, as previously reported.<xref rid="jah32122-bib-0013" ref-type="ref">13</xref>
</p><p>Baseline and disease characteristics were reported by treatment group for all randomized patients in DM and non&#x02010;DM groups. Treatment differences between ticagrelor and clopidogrel groups in PRU, percentage reduction from baseline in PRU, percentage IPA, and HPR rates were analyzed based on the pharmacodynamic population.</p></sec></sec><sec id="jah32122-sec-0009"><title>Results</title><sec id="jah32122-sec-0010"><title>Patient Population</title><p>Between July 2012 and June 2014, 100 patients were randomized to ticagrelor or clopidogrel. Of these, 36 patients had DM (n=20 in the ticagrelor group and n=16 in the clopidogrel group), and 64 were non&#x02010;DM (n=31 in the ticagrelor group and n=33 in the clopidogrel group) (<xref rid="jah32122-tbl-0001" ref-type="table-wrap">Table</xref>). The pharmacodynamic population consisted of 92 patients: 45 in the ticagrelor group (19 DM and 26 non&#x02010;DM) and 47 in the clopidogrel group (16 DM and 31 non&#x02010;DM). Eight patients were excluded from the pharmacodynamic population: 6 in the ticagrelor group (1 with predose PRU &#x0003c;150, 1 missing analyzable data, and 4 with a protocol deviation), and 2 in the clopidogrel group (both with a protocol deviation).</p><table-wrap id="jah32122-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics (All Randomized Patients)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Variable</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">DM (n=36)</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Non&#x02010;DM (n=64)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor (n=20)</th><th align="left" valign="top" rowspan="1" colspan="1">Clopidogrel (n=16)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor (n=31)</th><th align="left" valign="top" rowspan="1" colspan="1">Clopidogrel (n=33)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Treatment for DM, n</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Insulin only</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oral antidiabetic agents only</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Insulin and oral antidiabetic agents</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diet&#x02010;controlled</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, y, mean (SD)</td><td align="left" rowspan="1" colspan="1">59.1 (10.1)</td><td align="left" rowspan="1" colspan="1">64.9 (9.0)</td><td align="left" rowspan="1" colspan="1">0.079</td><td align="left" rowspan="1" colspan="1">60.8 (11.3)</td><td align="left" rowspan="1" colspan="1">62.1 (9.2)</td><td align="left" rowspan="1" colspan="1">0.601</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years, n (%)</td><td align="left" rowspan="1" colspan="1">4 (20.0)</td><td align="left" rowspan="1" colspan="1">8 (50.0)</td><td align="left" rowspan="1" colspan="1">0.061</td><td align="left" rowspan="1" colspan="1">11 (35.5)</td><td align="left" rowspan="1" colspan="1">11 (33.3)</td><td align="left" rowspan="1" colspan="1">0.854</td></tr><tr><td align="left" rowspan="1" colspan="1">Women, n (%)</td><td align="left" rowspan="1" colspan="1">7 (35.0)</td><td align="left" rowspan="1" colspan="1">5 (31.3)</td><td align="left" rowspan="1" colspan="1">0.818</td><td align="left" rowspan="1" colspan="1">10 (32.3)</td><td align="left" rowspan="1" colspan="1">8 (24.2)</td><td align="left" rowspan="1" colspan="1">0.475</td></tr><tr><td align="left" rowspan="1" colspan="1">Race, n (%)<xref ref-type="fn" rid="jah32122-note-0002">a</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.881</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">8 (47.1)</td><td align="left" rowspan="1" colspan="1">9 (60.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25 (86.2)</td><td align="left" rowspan="1" colspan="1">24 (77.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">7 (41.2)</td><td align="left" rowspan="1" colspan="1">5 (33.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4 (13.8)</td><td align="left" rowspan="1" colspan="1">6 (19.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other<xref ref-type="fn" rid="jah32122-note-0003">b</xref>
</td><td align="left" rowspan="1" colspan="1">2 (11.8)</td><td align="left" rowspan="1" colspan="1">1 (6.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI &#x0003e;30&#x000a0;kg/m<sup>2</sup>, n (%)<xref ref-type="fn" rid="jah32122-note-0004">c</xref>
</td><td align="left" rowspan="1" colspan="1">11 (55.0)</td><td align="left" rowspan="1" colspan="1">11 (68.8)</td><td align="left" rowspan="1" colspan="1">0.405</td><td align="left" rowspan="1" colspan="1">13 (43.3)</td><td align="left" rowspan="1" colspan="1">13 (39.4)</td><td align="left" rowspan="1" colspan="1">0.753</td></tr><tr><td align="left" colspan="7" rowspan="1">Cardiovascular risk factors, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidemia</td><td align="left" rowspan="1" colspan="1">15 (75.0)</td><td align="left" rowspan="1" colspan="1">15 (93.8)</td><td align="left" rowspan="1" colspan="1">0.138</td><td align="left" rowspan="1" colspan="1">23 (74.2)</td><td align="left" rowspan="1" colspan="1">27 (81.8)</td><td align="left" rowspan="1" colspan="1">0.466</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">19 (95.0)</td><td align="left" rowspan="1" colspan="1">15 (93.8)</td><td align="left" rowspan="1" colspan="1">0.877</td><td align="left" rowspan="1" colspan="1">25 (80.6)</td><td align="left" rowspan="1" colspan="1">33 (100)</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic kidney disease (GFR &#x0003c;60&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">3 (15.0)</td><td align="left" rowspan="1" colspan="1">4 (25.0)</td><td align="left" rowspan="1" colspan="1">0.458</td><td align="left" rowspan="1" colspan="1">4 (12.9)</td><td align="left" rowspan="1" colspan="1">3 (9.1)</td><td align="left" rowspan="1" colspan="1">0.629</td></tr><tr><td align="left" colspan="7" rowspan="1">Prior cardiovascular disease and cardiovascular procedures, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Congestive heart failure (past or current)</td><td align="left" rowspan="1" colspan="1">1 (5.0)</td><td align="left" rowspan="1" colspan="1">2 (12.5)</td><td align="left" rowspan="1" colspan="1">0.425</td><td align="left" rowspan="1" colspan="1">5 (16.1)</td><td align="left" rowspan="1" colspan="1">1 (3.0)</td><td align="left" rowspan="1" colspan="1">0.091</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral arterial occlusive disease</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">1 (3.0)</td><td align="left" rowspan="1" colspan="1">0.964</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke, any</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">1 (3.0)</td><td align="left" rowspan="1" colspan="1">0.964</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Transient ischemic attack, any</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (6.3)</td><td align="left" rowspan="1" colspan="1">0.264</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (3.0)</td><td align="left" rowspan="1" colspan="1">0.335</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior myocardial infarction</td><td align="left" rowspan="1" colspan="1">1 (5.0)</td><td align="left" rowspan="1" colspan="1">6 (37.5)</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">8 (25.8)</td><td align="left" rowspan="1" colspan="1">10 (30.3)</td><td align="left" rowspan="1" colspan="1">0.691</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PCI</td><td align="left" rowspan="1" colspan="1">8 (40.0)</td><td align="left" rowspan="1" colspan="1">5 (31.3)</td><td align="left" rowspan="1" colspan="1">0.560</td><td align="left" rowspan="1" colspan="1">11 (35.5)</td><td align="left" rowspan="1" colspan="1">17 (51.5)</td><td align="left" rowspan="1" colspan="1">0.201</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior coronary artery bypass graft</td><td align="left" rowspan="1" colspan="1">1 (5.0)</td><td align="left" rowspan="1" colspan="1">6 (37.5)</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">4 (12.9)</td><td align="left" rowspan="1" colspan="1">8 (24.2)</td><td align="left" rowspan="1" colspan="1">0.251</td></tr></tbody></table><table-wrap-foot><fn id="jah32122-note-0001"><p>BMI indicates body mass index; DM, diabetes mellitus; GFR, glomerular filtration rate; N/A, not applicable; PCI, percutaneous coronary intervention.</p></fn><fn id="jah32122-note-0002"><label>a</label><p>Five patients in the ticagrelor group (3 DM and 2 non&#x02010;DM) and 3 in the clopidogrel group (1 DM and 2 non&#x02010;DM) were missing race values.</p></fn><fn id="jah32122-note-0003"><label>b</label><p>Asian, American Indian, or Alaskan Native.</p></fn><fn id="jah32122-note-0004"><label>c</label><p>Data missing for 1 patient in the ticagrelor group (non&#x02010;DM).</p></fn></table-wrap-foot></table-wrap><p>Baseline characteristics are reported in the <xref rid="jah32122-tbl-0001" ref-type="table-wrap">Table</xref>. DM patients treated with clopidogrel were significantly more likely than ticagrelor&#x02010;treated patients to have had a prior myocardial infarction or to have undergone coronary artery bypass graft (both <italic>P</italic>=0.016), and they were also somewhat older (mean age 64.9&#x000a0;years versus 59.1&#x000a0;years [<italic>P</italic>=0.079], with 50% versus 20% aged &#x02265;65&#x000a0;years [<italic>P</italic>=0.061]).</p></sec><sec id="jah32122-sec-0011"><title>Pharmacodynamic Results</title><p>No statistically significant interaction effect between treatment group and diabetic status was observed for PRU levels across all time points. At 2&#x000a0;hours post&#x02010;LD (primary endpoint), mean (SD) PRU levels in DM patients were 130.1 (111.7) with ticagrelor and 287.6 (71.9) with clopidogrel, with a mean (95%CI) between&#x02010;treatment difference of &#x02212;157.5 (&#x02212;225.3, &#x02212;89.8; <italic>P</italic>&#x0003c;0.001) (Figure&#x000a0;<xref rid="jah32122-fig-0001" ref-type="fig">1</xref>). In non&#x02010;DM patients, PRU levels at 2&#x000a0;hours post&#x02010;LD were 75.3 (75.7) and 243.0 (72.4) with ticagrelor and clopidogrel, respectively, with a between&#x02010;treatment difference of &#x02212;167.7 (&#x02212;207.1, &#x02212;128.3; <italic>P</italic>&#x0003c;0.001).</p><fig fig-type="Figure" xml:lang="en" id="jah32122-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>P2Y<sub>12</sub> reaction units (PRU) at 2&#x000a0;hours after loading dose (LD) (pharmacodynamic population). At 2&#x000a0;hours post&#x02013;LD, mean (<styled-content style="fixed-case">SD</styled-content>) PRU levels were significantly reduced with ticagrelor vs clopidogrel in <styled-content style="fixed-case">DM</styled-content> and non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients. The mean (95%<styled-content style="fixed-case">CI</styled-content>) between&#x02010;treatment differences in each case were &#x02212;157.5 (&#x02212;225.3, &#x02212;89.8; <italic>P</italic>&#x0003c;0.001) and &#x02212;167.7 (&#x02212;207.1, &#x02212;128.3; <italic>P</italic>&#x0003c;0.001), respectively. <styled-content style="fixed-case">DM</styled-content> indicates diabetes mellitus.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e005650-g001"/></fig><p>At 0.5&#x000a0;hour post&#x02010;LD and end&#x02010;of&#x02010;PCI (mean 0.6&#x000a0;hour post&#x02010;LD) time points, there was no significant difference in mean PRU levels between ticagrelor and clopidogrel in the DM or non&#x02010;DM groups (Figure&#x000a0;<xref rid="jah32122-fig-0002" ref-type="fig">2</xref>). At 8&#x000a0;hours post&#x02010;LD, mean (SD) PRU levels remained significantly lower with ticagrelor versus clopidogrel in both DM patients (57.2 [57.5] versus 255.3 [85.7]; between&#x02010;treatment difference [95%CI] &#x02212;198.1 [&#x02212;249.7, &#x02212;146.6]; <italic>P</italic>&#x0003c;0.001) and non&#x02010;DM patients (34.3 [33.3] versus 173.1 [77.8]; &#x02212;138.8 [&#x02212;173.0, &#x02212;104.5]; <italic>P</italic>&#x0003c;0.001) (Figure&#x000a0;<xref rid="jah32122-fig-0002" ref-type="fig">2</xref>). In DM patients, the changes in PRU at 2&#x000a0;hours post&#x02010;LD represented mean reductions from baseline of 56.2% and 10.9% with ticagrelor and clopidogrel, respectively, with corresponding values in non&#x02010;DM patients of 73.2% and 14.1% (<italic>P</italic>&#x0003c;0.001 in each case) (Figure&#x000a0;<xref rid="jah32122-fig-0003" ref-type="fig">3</xref>A and <xref rid="jah32122-fig-0003" ref-type="fig">3</xref>B). The between&#x02010;treatment difference remained significant at 8&#x000a0;hours post&#x02010;LD (<italic>P</italic>&#x0003c;0.001). Mean percentage IPA was also significantly greater with ticagrelor versus clopidogrel at 2 and 8&#x000a0;hours post&#x02010;LD in DM and non&#x02010;DM patients (<italic>P</italic>&#x0003c;0.001 in each case) (Figure&#x000a0;<xref rid="jah32122-fig-0003" ref-type="fig">3</xref>C and <xref rid="jah32122-fig-0003" ref-type="fig">3</xref>D).</p><fig fig-type="Figure" xml:lang="en" id="jah32122-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Time course of P2Y<sub>12</sub> reaction units (<styled-content style="fixed-case">PRU</styled-content>) at 0.5, 2, and 8&#x000a0;hours after loading dose (<styled-content style="fixed-case">LD</styled-content>) and at the end of percutaneous coronary intervention (<styled-content style="fixed-case">PCI</styled-content>) (pharmacodynamic population). Mean (<styled-content style="fixed-case">SD</styled-content>) <styled-content style="fixed-case">PRU</styled-content> levels remained significantly lower with ticagrelor vs clopidogrel at 8&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content> in <styled-content style="fixed-case">DM</styled-content> patients (57.2 [57.5] vs 255.3 [85.7]; between&#x02010;treatment difference [95%<styled-content style="fixed-case">CI</styled-content>] &#x02212;198.1 [&#x02212;249.7, &#x02212;146.6]; <italic>P</italic>&#x0003c;0.001) and non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients (34.3 [33.3] vs 173.1 [77.8]; &#x02212;138.8 [&#x02212;173.0, &#x02212;104.5]; <italic>P</italic>&#x0003c;0.001). *Mean time to end of <styled-content style="fixed-case">PCI</styled-content> was 0.6&#x000a0;hour. <styled-content style="fixed-case">DM</styled-content> indicates diabetes mellitus.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e005650-g002"/></fig><fig fig-type="Figure" xml:lang="en" id="jah32122-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Percentage change from baseline in platelet reactivity. Mean percentage reduction from baseline in P2Y<sub>12</sub> reaction units (<styled-content style="fixed-case">PRU</styled-content>) in (A) diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) patients and (B) non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients; and mean percentage inhibition of platelet aggregation in (C) <styled-content style="fixed-case">DM</styled-content> patients and (D) non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients (pharmacodynamic population). Mean percentage change in <styled-content style="fixed-case">PRU</styled-content> and <styled-content style="fixed-case">IPA</styled-content> was significantly greater with ticagrelor vs clopidogrel at 2 and 8&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content> in both <styled-content style="fixed-case">DM</styled-content> and non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients (<italic>P</italic>&#x0003c;0.001 in each case). *<italic>P</italic>&#x0003c;0.001 for ticagrelor vs clopidogrel. <sup>&#x02020;</sup>Mean time to end of <styled-content style="fixed-case">PCI</styled-content> was 0.6&#x000a0;hour. <styled-content style="fixed-case">IPA</styled-content> indicates inhibition of platelet aggregation; <styled-content style="fixed-case">LD</styled-content>, loading dose; <styled-content style="fixed-case">PCI</styled-content>, percutaneous coronary intervention.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e005650-g003"/></fig><p>Mean PRU levels in DM versus non&#x02010;DM patients were not significantly different at any time point in the ticagrelor group, but were significantly different at 8&#x000a0;hours post&#x02010;LD in the clopidogrel group (255.3 versus 173.1; <italic>P</italic>=0.002) (Figure&#x000a0;<xref rid="jah32122-fig-0004" ref-type="fig">4</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32122-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>P2Y<sub>12</sub> reaction units (<styled-content style="fixed-case">PRU</styled-content>) levels in (A) ticagrelor patients and (B) clopidogrel patients by diabetic status at 0.5, 2, and 8&#x000a0;hours after loading dose (<styled-content style="fixed-case">LD</styled-content>) and at end of percutaneous coronary intervention (<styled-content style="fixed-case">PCI</styled-content>) (pharmacodynamic population). Mean <styled-content style="fixed-case">PRU</styled-content> levels in <styled-content style="fixed-case">DM</styled-content> vs non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients were similar at each time point in the ticagrelor group but were significantly different at 8&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content> in the clopidogrel group (<italic>P</italic>=0.002). *<italic>P</italic>=0.002 for <styled-content style="fixed-case">DM</styled-content> vs non&#x02010;<styled-content style="fixed-case">DM</styled-content>. <sup>&#x02020;</sup>Mean time to end of <styled-content style="fixed-case">PCI</styled-content> was 0.6&#x000a0;hour.</p></caption><graphic id="nlm-graphic-7" xlink:href="JAH3-6-e005650-g004"/></fig><p>Ticagrelor significantly reduced the rates of HPR, compared with clopidogrel, at 2 and 8&#x000a0;hours post&#x02010;LD, irrespective of diabetic status. At 2&#x000a0;hours post&#x02010;LD, HPR was present in 21.1% of DM patients in the ticagrelor arm and in 93.3% in the clopidogrel arm (<italic>P</italic>&#x0003c;0.001), and in 7.7% and 71.0% of non&#x02010;DM patients (<italic>P</italic>&#x0003c;0.001), respectively (Figure&#x000a0;<xref rid="jah32122-fig-0005" ref-type="fig">5</xref>). Corresponding values at 8&#x000a0;hours post&#x02010;LD were 5.9% and 81.3% of DM patients (<italic>P</italic>&#x0003c;0.001), and 0.0% and 37.9% of non&#x02010;DM patients (<italic>P</italic>&#x0003c;0.001) (Figure&#x000a0;<xref rid="jah32122-fig-0005" ref-type="fig">5</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32122-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Percentage of (A) diabetes mellitus (<styled-content style="fixed-case">DM</styled-content>) patients and (B) non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients with high on&#x02010;treatment platelet reactivity (HPR: P2Y<sub>12</sub> reaction units [<styled-content style="fixed-case">PRU</styled-content>] &#x02265;208) (pharmacodynamic population). Rates of <styled-content style="fixed-case">HPR</styled-content> were significantly lower with ticagrelor vs clopidogrel at 2 and 8&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content> in both <styled-content style="fixed-case">DM</styled-content> and non&#x02010;<styled-content style="fixed-case">DM</styled-content> patients (<italic>P</italic>&#x0003c;0.001 in each case). At 8&#x000a0;hours post&#x02010;<styled-content style="fixed-case">LD</styled-content>, 81.3% of clopidogrel&#x02010;treated <styled-content style="fixed-case">DM</styled-content> patients still had <styled-content style="fixed-case">HPR</styled-content> compared with only 5.9% of those treated with ticagrelor. *<italic>P</italic>&#x0003c;0.001 for ticagrelor vs clopidogrel. <sup>&#x02020;</sup>Mean time to end of <styled-content style="fixed-case">PCI</styled-content> was 0.6&#x000a0;hour. <styled-content style="fixed-case">LD</styled-content> indicates loading dose; <styled-content style="fixed-case">PCI</styled-content>, percutaneous coronary intervention.</p></caption><graphic id="nlm-graphic-9" xlink:href="JAH3-6-e005650-g005"/></fig><p>Exploratory analyses using the repeated&#x02010;measures model showed that, within both the DM and non&#x02010;DM groups, the treatment effects across time points on PRU between ticagrelor and clopidogrel were all statistically significant (<italic>P</italic>&#x0003c;0.001).</p></sec></sec><sec id="jah32122-sec-0012"><title>Discussion</title><p>The results of this analysis indicate that ticagrelor has consistently more potent antiplatelet effects compared with clopidogrel in both DM and non&#x02010;DM patients presenting with a low&#x02010;risk ACS and undergoing ad hoc PCI. Importantly, the study also confirms how clopidogrel&#x02010;induced antiplatelet effects are markedly impaired among DM patients, with HPR rates &#x0003e;80% even at 8&#x000a0;hours after LD administration. Given the prognostic implications associated with HPR, the more favorable pharmacodynamic effects of ticagrelor as shown in this study make this a more desirable agent, particularly among DM patients, including those with low&#x02010;risk ACS who have not been pretreated with a P2Y<sub>12</sub> receptor inhibitor undergoing ad hoc PCI. These findings are of clinical relevance, given that a considerable number of ACS patients undergoing ad hoc PCI are not pretreated with a P2Y<sub>12</sub> receptor inhibitor, particularly in the United States, underscoring the need for effective platelet inhibition in the peri&#x02010;PCI period among these patients.<xref rid="jah32122-bib-0014" ref-type="ref">14</xref>, <xref rid="jah32122-bib-0015" ref-type="ref">15</xref>, <xref rid="jah32122-bib-0016" ref-type="ref">16</xref>
</p><p>Enhanced platelet reactivity in DM patients results from a complex process of interaction between biochemical factors such as hyperglycemia, insulin resistance/deficiency, oxidative stress, endothelial dysfunction, and lipid abnormalities, all leading to increased expression of platelet glycoprotein IIb/IIIa receptors, loss of insulin&#x02010;related inhibition of the P2Y<sub>12</sub> pathway, upregulation of genes involved in thrombus generation, increased generation of adhesion molecules, and several other features of increased platelet reactivity.<xref rid="jah32122-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32122-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32122-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32122-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32122-bib-0007" ref-type="ref">7</xref> These findings contribute to the higher rates of HPR observed in DM patients compared with non&#x02010;DM patients and therefore can explain why DM patients carry a higher risk of thrombotic complications.<xref rid="jah32122-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32122-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32122-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32122-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32122-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32122-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32122-bib-0009" ref-type="ref">9</xref> Overall, these observations underscore the need for optimizing platelet inhibitory effects in DM patients.</p><p>In the acute phase of treatment, glycoprotein IIb/IIIa receptor inhibitors have been shown to achieve potent platelet inhibitory effects and to be particularly efficacious, including reducing mortality, among DM patients presenting with an ACS.<xref rid="jah32122-bib-0017" ref-type="ref">17</xref> However, these agents have been largely abandoned in routine practice given the increased risk of bleeding complications.<xref rid="jah32122-bib-0018" ref-type="ref">18</xref> Until the availability of the newer&#x02010;generation P2Y<sub>12</sub> receptor inhibitors prasugrel and ticagrelor, strategies to optimize platelet inhibition in DM patients have included high clopidogrel dosing regimens and adjunctive therapy with cilostazol.<xref rid="jah32122-bib-0019" ref-type="ref">19</xref>, <xref rid="jah32122-bib-0020" ref-type="ref">20</xref>
</p><p>The association between HPR and variable response to clopidogrel has preceded the development of more potent antiplatelet agents that provide more rapid and predictable pharmacodynamic effects in both DM and non&#x02010;DM populations.<xref rid="jah32122-bib-0021" ref-type="ref">21</xref>, <xref rid="jah32122-bib-0022" ref-type="ref">22</xref> In the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS)&#x02010;3 study, for example, prasugrel 60&#x000a0;mg LD followed by 10&#x000a0;mg once daily was shown to result in higher inhibitory antiplatelet activity than high&#x02010;dose clopidogrel (600&#x000a0;mg LD followed by 150&#x000a0;mg once daily) in DM patients with coronary artery disease (CAD).<xref rid="jah32122-bib-0023" ref-type="ref">23</xref> Similarly, a subgroup analysis from a study of Hispanic patients with stable CAD showed that ticagrelor 180&#x000a0;mg LD followed by 90&#x000a0;mg twice daily resulted in faster and greater inhibition of platelet activity compared with clopidogrel 600&#x000a0;mg LD then 75&#x000a0;mg once daily in DM and non&#x02010;DM patients, including significantly lower rates of HPR.<xref rid="jah32122-bib-0024" ref-type="ref">24</xref> These findings are in line with the post hoc analysis presented here, which also demonstrated a rapid and more intensive antiplatelet effect with ticagrelor, compared with clopidogrel, in both DM and non&#x02010;DM patients, in this case with troponin&#x02010;negative ACS. Furthermore, the OPTIMUS&#x02010;4 trial conducted in type 2 DM patients with CAD found that platelet reactivity was significantly reduced compared with baseline values with both prasugrel and ticagrelor LD and maintenance doses.<xref rid="jah32122-bib-0025" ref-type="ref">25</xref> The degree of platelet inhibition was similar with both drugs at all time points according to all assays except for VerifyNow<sup>&#x000ae;</sup>, which showed a greater reduction in PRU levels with ticagrelor at 1&#x000a0;week.</p><p>The observed pharmacodynamic effects of ticagrelor and clopidogrel illustrate some key differences between the 2 drugs. Whereas ticagrelor is a direct&#x02010;acting agent, clopidogrel is a prodrug, requiring metabolic activation in the liver by cytochrome P450.<xref rid="jah32122-bib-0026" ref-type="ref">26</xref> Moreover, a large proportion of the clopidogrel prodrug is inactivated by esterases in the blood before it even reaches the liver.<xref rid="jah32122-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32122-bib-0022" ref-type="ref">22</xref> In DM patients, the reduced responsiveness is amplified by impaired metabolism of&#x000a0;clopidogrel, resulting in ~40% reduced exposure to the active&#x000a0;metabolite compared with non&#x02010;DM patients.<xref rid="jah32122-bib-0007" ref-type="ref">7</xref> Because ticagrelor does not follow the same metabolic pathway as clopidogrel, this explains, at least in part, the disparity between the 2 drugs in terms of speed and degree of platelet reactivity and HPR rates in DM and non&#x02010;DM patients. There is also a proportion of patients who are poor responders to clopidogrel, including&#x02014;but far from limited to&#x02014;those with genetic variations, such as CYP2C19 polymorphisms.<xref rid="jah32122-bib-0027" ref-type="ref">27</xref>, <xref rid="jah32122-bib-0028" ref-type="ref">28</xref>, <xref rid="jah32122-bib-0029" ref-type="ref">29</xref>, <xref rid="jah32122-bib-0030" ref-type="ref">30</xref> Data from the Escalating Clopidogrel by Involving a Genetic Strategy&#x02014;Thrombolysis in Myocardial Infarction 56 (ELEVATE&#x02010;TIMI 56) trial in patients with CAD showed that those with both DM and the CYP2C19 polymorphism required 4&#x02010;fold increases in the clopidogrel maintenance dose to achieve the platelet inhibitory effects seen in patients without these risk factors.<xref rid="jah32122-bib-0031" ref-type="ref">31</xref>
</p><p>The favorable pharmacodynamic profile of ticagrelor irrespective of DM status, as shown in this study, may explain the consistent benefit of ticagrelor in DM and non&#x02010;DM patients in the PLATelet Inhibition and Patient Outcomes (PLATO) trial, a large&#x02010;scale clinical investigation of high&#x02010;risk patients with ACS, demonstrating superior outcomes with ticagrelor.<xref rid="jah32122-bib-0012" ref-type="ref">12</xref>, <xref rid="jah32122-bib-0032" ref-type="ref">32</xref> In the diabetes substudy from PLATO, ticagrelor achieved reductions in the primary composite endpoint, all&#x02010;cause mortality, and stent thrombosis, compared with clopidogrel, with no increase in major bleeding. The results were also consistent for DM patients with or without ongoing insulin treatment.<xref rid="jah32122-bib-0032" ref-type="ref">32</xref> More recently, a secondary prevention study composed of patients with prior (1&#x02010;3&#x000a0;years) myocardial infarction showed a consistent ischemic benefit, albeit at the expense of more bleeding, of ticagrelor versus placebo in DM and non&#x02010;DM patients.<xref rid="jah32122-bib-0033" ref-type="ref">33</xref> The clinical benefit of ticagrelor versus placebo in type 2 DM patients with stable CAD not undergoing PCI is currently unknown and is being evaluated in the ongoing Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) trial (NCT01991795). The benefit of ticagrelor in stable patients undergoing elective PCI is unknown and will be investigated in the Assessment of Loading with the P2Y<sub>12</sub> Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (ALPHEUS) trial, which will also include both DM and non&#x02010;DM patients (NCT02617290).</p><p>The Ad Hoc PCI study enrolled low&#x02010;risk patients undergoing PCI, and the results observed in this study, in combination with the clinical ischemic benefits seen in PLATO, may be specific to patients undergoing PCI, as there was no comparison with patients not treated with PCI. To this end, ticagrelor monotherapy did not show any significant benefit compared with clopidogrel monotherapy for ischemic event reduction in patients with peripheral artery disease in the Examining Use of tiCagreLor In paD (EUCLID) trial<xref rid="jah32122-bib-0034" ref-type="ref">34</xref> or compared with aspirin for the prevention of recurrent events in patients with prior stroke or transient ischemic attack in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial.<xref rid="jah32122-bib-0035" ref-type="ref">35</xref> Although there was no treatment interaction by diabetic status in the latter study, the results from our current study in the context of these recent primary and secondary prevention trials suggest that the benefit of ticagrelor, in addition to aspirin, may be limited to DM patients undergoing PCI.</p><p>In this study, there were 3 subjects with diet&#x02010;controlled DM. In order to assess a potential interaction between diet&#x02010;controlled DM and those diabetic subjects treated with antidiabetic therapy, an additional sensitivity analysis excluding the 3 diet&#x02010;controlled patients was performed on the primary endpoint of PRU at 2&#x000a0;hours post&#x02010;LD for the DM group. The result is consistent with the primary result with these patients included.</p><p>The results of the current study demonstrate the pharmacodynamic benefits (greater inhibition of platelet reactivity and reduced rates of HPR) of intensified antiplatelet therapy in low&#x02010;risk ACS diabetic patients with a ticagrelor LD versus a clopidogrel LD in the peri&#x02010;intervention period. How this pharmacodynamic benefit translates into potential therapeutic strategies (such as intensified antiplatelet therapy with ticagrelor in the peri&#x02010;intervention period followed by less intensive antiplatelet therapy) should be the focus of further clinical studies.</p><sec id="jah32122-sec-0013"><title>Study Limitations</title><p>The Ad Hoc PCI study is a pharmacodynamic study and therefore was not designed or powered to assess clinical events. The safety and efficacy of ticagrelor in elective or urgent PCI, including high&#x02010;risk patients with DM, are currently being evaluated in a separate study (NCT02270242). Furthermore, this was a post hoc analysis, and patients were not randomized within DM and non&#x02010;DM groups. Also, due to the small numbers of patients in each group (DM and non&#x02010;DM), the results should be interpreted with caution.</p><p>The current study demonstrates that mean (SD) baseline PRU levels in the ticagrelor group were similar in DM and non&#x02010;DM patients: 290.4 (74.6) and 282.6 (56.1), respectively. Many studies have shown that baseline platelet reactivity is actually higher in diabetic patients. The discrepant findings from our study may be the result of an artifact due to the relatively small number of subjects, in addition to the broad range of values within the DM and non&#x02010;DM patient groups: median (min&#x02010;max) 282 (163&#x02010;451) versus 276 (197&#x02010;418), respectively.</p><p>It should also be noted that there were differences in several baseline characteristics between the randomized treatment arms when stratified by DM status (ie, age, prior myocardial infarction, and prior coronary artery bypass grafting). The influence of these baseline characteristics, and that of the different numbers of patients excluded from analysis in each treatment arm when stratified by DM status, on platelet reactivity cannot be excluded. The use of only 1 platelet function test may also be considered a limitation, as well as the lack of pharmacokinetic measurements in this analysis. Furthermore, HbA1c values were not collected prospectively, so we were unable to determine any association between HbA1c levels and platelet response as a marker of well versus poorly controlled DM. Finally, this study included only P2Y<sub>12</sub> inhibitor&#x02010;naive patients, and the pharmacodynamic effects of ticagrelor in patients pretreated with clopidogrel were not explored.</p></sec></sec><sec id="jah32122-sec-0014"><title>Conclusions</title><p>In troponin&#x02010;negative ACS patients undergoing ad hoc PCI, compared with clopidogrel, ticagrelor was associated with more rapid and enhanced platelet inhibition irrespective of diabetic status. Importantly, HPR rates remained markedly elevated in DM patients treated with clopidogrel, a phenomenon that was largely overcome by ticagrelor therapy. The results indicate that ticagrelor may be an important option for nonpretreated low&#x02010;risk ACS patients with DM undergoing ad hoc PCI.</p></sec><sec id="jah32122-sec-0015"><title>Author Contributions</title><p>We would like to thank the patients who participated in this study and all the Ad Hoc PCI study Principal Investigators not listed as authors for their contributions to the study. Medical writing support was provided by Liz Anfield, Prime, Knutsford, Cheshire, UK, funded by AstraZeneca. Design and conduct of the study, as well as analysis of study data and opinions, conclusions, and interpretation of the data, are the responsibility of the authors.</p></sec><sec id="jah32122-sec-0017"><title>Sources of Funding</title><p>The Ad Hoc PCI study was funded by AstraZeneca.</p></sec><sec id="jah32122-sec-0018"><title>Disclosures</title><p>Dr Angiolillo has received payment as an individual for (1) consulting fees or honoraria from Amgen, Bayer, Sanofi, Eli Lilly, Daiichi&#x02010;Sankyo, The Medicines Company, AstraZeneca, Merck, Abbott Vascular, Pfizer, and PLx Pharma; (2) participation in review activities from CeloNova, Johnson &#x00026; Johnson, and St. Jude Medical; and (3) institutional payments for grants from GlaxoSmithKline, Eli Lilly, Daiichi&#x02010;Sankyo, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead. Dr Waksman has received consulting fees or honoraria from AstraZeneca, Abbott Vascular, Boston Scientific, Medtronic Vascular, Biotronik, and Biosensors; and received institutional payments for investigator grants from AstraZeneca, Boston Scientific, Edwards Life Sciences, Medtronic Vascular, Biotronik, Biosensors, and Infraredx. Dr Dangas has received research grants from DSI/Eli Lilly, Bristol&#x02010;Myers Squibb/Sanofi&#x02010;Aventis, AstraZeneca, and The Medicines Company; and consulting or advisory board fees from AstraZeneca, CSL Behring, Janssen Pharmaceuticals, Inc., and Osprey Medical, Inc. Dr Khan is an employee of AstraZeneca. Dr Carlson is an employee of AstraZeneca. Dr Zhao is a consultant to AstraZeneca. Dr Teng is an employee of AstraZeneca. Dr Mehran has received research grants from DSI/Eli Lilly, Bristol&#x02010;Myers Squibb/Sanofi&#x02010;Aventis, AstraZeneca, and The Medicines Company; and consulting or advisory board fees from AstraZeneca, CSL Behring, Janssen Pharmaceuticals, Inc., and Osprey Medical, Inc. The remaining authors have no disclosures to report.</p></sec></body><back><ack id="jah32122-sec-0016"><title>Acknowledgments</title><p>AstraZeneca participated in the design and conduct of the study and in the collection, management, analysis, and interpretation of the data. Four co&#x02010;authors from AstraZeneca (Dr Khan, Dr Carlson, Dr Zhao, and Dr Teng) contributed to preparation of the manuscript.</p></ack><ref-list content-type="cited-references" id="jah32122-bibl-0001"><title>References</title><ref id="jah32122-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32122-cit-0001">
<string-name>
<surname>Roffi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Kappetein</surname>
<given-names>AP</given-names>
</string-name>. <article-title>Current concepts on coronary revascularization in diabetic patients</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>2748</fpage>&#x02013;<lpage>2757</lpage>.<pub-id pub-id-type="pmid">21893486</pub-id></mixed-citation></ref><ref id="jah32122-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32122-cit-0002">
<string-name>
<surname>Moreno</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Murcia</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Palacios</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Leon</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Bernardi</surname>
<given-names>VH</given-names>
</string-name>, <string-name>
<surname>Fuster</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Fallon</surname>
<given-names>JT</given-names>
</string-name>. <article-title>Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>102</volume>:<fpage>2180</fpage>&#x02013;<lpage>2184</lpage>.<pub-id pub-id-type="pmid">11056089</pub-id></mixed-citation></ref><ref id="jah32122-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32122-cit-0003">
<string-name>
<surname>Ferreiro</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Diabetes and antiplatelet therapy in acute coronary syndrome</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>798</fpage>&#x02013;<lpage>813</lpage>.<pub-id pub-id-type="pmid">21343595</pub-id></mixed-citation></ref><ref id="jah32122-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32122-cit-0004">
<string-name>
<surname>Rollini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Muniz&#x02010;Lozano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Platelet function profiles in patients with diabetes mellitus</article-title>. <source>J Cardiovasc Transl Res</source>. <year>2013</year>;<volume>6</volume>:<fpage>329</fpage>&#x02013;<lpage>345</lpage>.<pub-id pub-id-type="pmid">23404189</pub-id></mixed-citation></ref><ref id="jah32122-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32122-cit-0005">
<string-name>
<surname>Park</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rollini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Antithrombotic therapy for secondary prevention in patients with diabetes mellitus and coronary artery disease</article-title>. <source>Circ J</source>. <year>2016</year>;<volume>80</volume>:<fpage>791</fpage>&#x02013;<lpage>801</lpage>.<pub-id pub-id-type="pmid">26984587</pub-id></mixed-citation></ref><ref id="jah32122-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32122-cit-0006">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;Ortiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bernardo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ramirez</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sabate</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jimenez&#x02010;Quevedo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hernandez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Escaned</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alfonso</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Banuelos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Macaya</surname>
<given-names>C</given-names>
</string-name>. <article-title>Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment</article-title>. <source>Diabetes</source>. <year>2005</year>;<volume>54</volume>:<fpage>2430</fpage>&#x02013;<lpage>2435</lpage>.<pub-id pub-id-type="pmid">16046311</pub-id></mixed-citation></ref><ref id="jah32122-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32122-cit-0007">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Jakubowski</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Ferreiro</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Tello&#x02010;Montoliu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rollini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ueno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Darlington</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Desai</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Moser</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Sugidachi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Guzman</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Impaired responsiveness to the platelet P2Y<sub>12</sub> receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>1005</fpage>&#x02013;<lpage>1014</lpage>.<pub-id pub-id-type="pmid">25190236</pub-id></mixed-citation></ref><ref id="jah32122-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32122-cit-0008">
<string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Bonello</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Aradi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Stone</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Curzen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Geisler</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ten Berg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kirtane</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Siller&#x02010;Matula</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mahla</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Waksman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Alexopoulos</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Marcucci</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Reny</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Trenk</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sibbing</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Consensus and update on the definition of on&#x02010;treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>:<fpage>2261</fpage>&#x02013;<lpage>2273</lpage>.<pub-id pub-id-type="pmid">24076493</pub-id></mixed-citation></ref><ref id="jah32122-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32122-cit-0009">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Bernardo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sabate</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jimenez&#x02010;Quevedo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Palazuelos</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hernandez&#x02010;Antolin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Escaned</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alfonso</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Banuelos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Guzman</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Macaya</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;Ortiz</surname>
<given-names>A</given-names>
</string-name>. <article-title>Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>:<fpage>1541</fpage>&#x02013;<lpage>1547</lpage>.<pub-id pub-id-type="pmid">17936152</pub-id></mixed-citation></ref><ref id="jah32122-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32122-cit-0010">
<string-name>
<surname>Capodanno</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dharmashankar</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y<sub>12</sub> receptor antagonist</article-title>. <source>Expert Rev Cardiovasc Ther</source>. <year>2010</year>;<volume>8</volume>:<fpage>151</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">20136601</pub-id></mixed-citation></ref><ref id="jah32122-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32122-cit-0011">
<string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Novel antiplatelet agents in acute coronary syndrome</article-title>. <source>Nat Rev Cardiol</source>. <year>2015</year>;<volume>12</volume>:<fpage>30</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">25286881</pub-id></mixed-citation></ref><ref id="jah32122-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32122-cit-0012">
<string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Budaj</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Emanuelsson</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Horrow</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Husted</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Scirica</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Skene</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Freij</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Thorsen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Ticagrelor versus clopidogrel in patients with acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>:<fpage>1045</fpage>&#x02013;<lpage>1057</lpage>.<pub-id pub-id-type="pmid">19717846</pub-id></mixed-citation></ref><ref id="jah32122-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32122-cit-0013">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Waksman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sweeny</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Raveendran</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mehran</surname>
<given-names>R</given-names>
</string-name>. <article-title>Effects of ticagrelor versus clopidogrel in troponin&#x02010;negative patients with low&#x02010;risk ACS undergoing ad hoc PCI</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>:<fpage>603</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">26868683</pub-id></mixed-citation></ref><ref id="jah32122-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32122-cit-0014">
<string-name>
<surname>Fan</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Plent</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Prats</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Deliargyris</surname>
<given-names>EN</given-names>
</string-name>. <article-title>Trends in P2Y<sub>12</sub> inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice</article-title>. <source>Am J Cardiol</source>. <year>2016</year>;<volume>117</volume>:<fpage>1439</fpage>&#x02013;<lpage>1443</lpage>.<pub-id pub-id-type="pmid">27001447</pub-id></mixed-citation></ref><ref id="jah32122-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32122-cit-0015">
<string-name>
<surname>Capodanno</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2015</year>;<volume>8</volume>:<fpage>e002301</fpage>.<pub-id pub-id-type="pmid">25717045</pub-id></mixed-citation></ref><ref id="jah32122-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32122-cit-0016">
<string-name>
<surname>Capodanno</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Reviewing the controversy surrounding pre&#x02010;treatment with P2Y<sub>12</sub> inhibitors in acute coronary syndrome patients</article-title>. <source>Expert Rev Cardiovasc Ther</source>. <year>2016</year>;<volume>14</volume>:<fpage>811</fpage>&#x02013;<lpage>820</lpage>.<pub-id pub-id-type="pmid">26953527</pub-id></mixed-citation></ref><ref id="jah32122-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32122-cit-0017">
<string-name>
<surname>Roffi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chew</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Mukherjee</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Kleiman</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Theroux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non&#x02010;ST&#x02010;segment&#x02010;elevation acute coronary syndromes</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>:<fpage>2767</fpage>&#x02013;<lpage>2771</lpage>.<pub-id pub-id-type="pmid">11733392</pub-id></mixed-citation></ref><ref id="jah32122-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32122-cit-0018">
<string-name>
<surname>Mu&#x000f1;iz&#x02010;Lozano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rollini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice</article-title>. <source>Ther Adv Cardiovasc Dis</source>. <year>2013</year>;<volume>7</volume>:<fpage>197</fpage>&#x02013;<lpage>213</lpage>.<pub-id pub-id-type="pmid">23818658</pub-id></mixed-citation></ref><ref id="jah32122-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32122-cit-0019">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Shoemaker</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Desai</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Charlton</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Bernardo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Zenni</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Guzman</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>115</volume>:<fpage>708</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">17261652</pub-id></mixed-citation></ref><ref id="jah32122-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32122-cit-0020">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Capranzano</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aslam</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Desai</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Charlton</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Box</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Shoemaker</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Zenni</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Guzman</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>TA</given-names>
</string-name>. <article-title>A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS&#x02010;2 study</article-title>. <source>Eur Heart J</source>. <year>2008</year>;<volume>29</volume>:<fpage>2202</fpage>&#x02013;<lpage>2211</lpage>.<pub-id pub-id-type="pmid">18567918</pub-id></mixed-citation></ref><ref id="jah32122-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32122-cit-0021">
<string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rollini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Novel antiplatelet agents: the current state and what is coming down the pike</article-title>. <source>Prog Cardiovasc Dis</source>. <year>2015</year>;<volume>58</volume>:<fpage>267</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">26277706</pub-id></mixed-citation></ref><ref id="jah32122-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32122-cit-0022">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;Ortiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bernardo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Alfonso</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Macaya</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>49</volume>:<fpage>1505</fpage>&#x02013;<lpage>1516</lpage>.<pub-id pub-id-type="pmid">17418288</pub-id></mixed-citation></ref><ref id="jah32122-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32122-cit-0023">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Badimon</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Saucedo</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Frelinger</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Jakubowski</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ojeh</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Effron</surname>
<given-names>MB</given-names>
</string-name>. <article-title>A pharmacodynamic comparison of prasugrel vs. high&#x02010;dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti&#x02010;Platelet Therapy In diabetes MellitUS (OPTIMUS)&#x02010;3 Trial</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>838</fpage>&#x02013;<lpage>846</lpage>.<pub-id pub-id-type="pmid">21252171</pub-id></mixed-citation></ref><ref id="jah32122-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32122-cit-0024">
<string-name>
<surname>Clavijo</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Maya</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Caplan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus</article-title>. <source>Cardiovasc Revasc Med</source>. <year>2015</year>;<volume>16</volume>:<fpage>450</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">26440227</pub-id></mixed-citation></ref><ref id="jah32122-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32122-cit-0025">
<string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rollini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Aggarwal</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Duarte</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kureti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Durairaj</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Been</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zenni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Guzman</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>D</given-names>
</string-name>. <article-title>Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease. The OPTIMUS (Optimizing Antiplatlet Therapy in Diabetes Mellitus)&#x02010;4 study</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>134</volume>:<fpage>780</fpage>&#x02013;<lpage>792</lpage>.<pub-id pub-id-type="pmid">27559041</pub-id></mixed-citation></ref><ref id="jah32122-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32122-cit-0026">
<string-name>
<surname>Ferri</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Corsini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bellosta</surname>
<given-names>S</given-names>
</string-name>. <article-title>Pharmacology of the new P2Y<sub>12</sub> receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties</article-title>. <source>Drugs</source>. <year>2013</year>;<volume>73</volume>:<fpage>1681</fpage>&#x02013;<lpage>1709</lpage>.<pub-id pub-id-type="pmid">24114622</pub-id></mixed-citation></ref><ref id="jah32122-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32122-cit-0027">
<string-name>
<surname>Price</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lillie</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>EN</given-names>
</string-name>, <string-name>
<surname>Tisch</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Schork</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Teirstein</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Influence of genetic polymorphisms on the effect of high&#x02010; and standard&#x02010;dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>59</volume>:<fpage>1928</fpage>&#x02013;<lpage>1937</lpage>.<pub-id pub-id-type="pmid">22624833</pub-id></mixed-citation></ref><ref id="jah32122-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah32122-cit-0028">
<string-name>
<surname>Shuldiner</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>O'Connell</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Gandhi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Horenstein</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Damcott</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Pakyz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Pollin</surname>
<given-names>TI</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Parsa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Faraday</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Herzog</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>:<fpage>849</fpage>&#x02013;<lpage>857</lpage>.<pub-id pub-id-type="pmid">19706858</pub-id></mixed-citation></ref><ref id="jah32122-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah32122-cit-0029">
<string-name>
<surname>Mega</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Hochholzer</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Frelinger</surname>
<given-names>AL</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Kluk</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Kereiakes</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Isserman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Ruff</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Contant</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pencina</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Scirica</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Longtine</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>306</volume>:<fpage>2221</fpage>&#x02013;<lpage>2228</lpage>.<pub-id pub-id-type="pmid">22088980</pub-id></mixed-citation></ref><ref id="jah32122-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah32122-cit-0030">
<string-name>
<surname>Mega</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Collet</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Antman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Bliden</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Danchin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Giusti</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gurbel</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Horne</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Hulot</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kastrati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Montalescot</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sibbing</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Trenk</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Reduced&#x02010;function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta&#x02010;analysis</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>304</volume>:<fpage>1821</fpage>&#x02013;<lpage>1830</lpage>.<pub-id pub-id-type="pmid">20978260</pub-id></mixed-citation></ref><ref id="jah32122-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah32122-cit-0031">
<string-name>
<surname>Carreras</surname>
<given-names>ET</given-names>
</string-name>, <string-name>
<surname>Hochholzer</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Frelinger</surname>
<given-names>AL</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Nordio</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>O'Donoghue</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Mega</surname>
<given-names>JL</given-names>
</string-name>. <article-title>Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE&#x02010;TIMI 56 Trial</article-title>. <source>Thromb Haemost</source>. <year>2016</year>;<volume>116</volume>:<fpage>69</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">27009617</pub-id></mixed-citation></ref><ref id="jah32122-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah32122-cit-0032">
<string-name>
<surname>James</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Cornel</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Erlinge</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Husted</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kontny</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Maya</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nicolau</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Spinar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>. <article-title>Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial</article-title>. <source>Eur Heart J</source>. <year>2010</year>;<volume>31</volume>:<fpage>3006</fpage>&#x02013;<lpage>3016</lpage>.<pub-id pub-id-type="pmid">20802246</pub-id></mixed-citation></ref><ref id="jah32122-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah32122-cit-0033">
<string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Bonaca</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Bansilal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Im</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>. <article-title>Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS&#x02010;TIMI 54</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>:<fpage>2732</fpage>&#x02013;<lpage>2740</lpage>.<pub-id pub-id-type="pmid">27046160</pub-id></mixed-citation></ref><ref id="jah32122-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah32122-cit-0034">
<string-name>
<surname>Jones</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Baumgartner</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hiatt</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Heizer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Conte</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Katona</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Norgren</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Blomster</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Millegard</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Reist</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Fowkes</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>241</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">27840336</pub-id></mixed-citation></ref><ref id="jah32122-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah32122-cit-0035">
<string-name>
<surname>Johnston</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Amarenco</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Albers</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Denison</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Easton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jonasson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Minematsu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Molina</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>KS</given-names>
</string-name>. <article-title>Ticagrelor versus aspirin in acute stroke or transient ischemic attack</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>35</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">27160892</pub-id></mixed-citation></ref></ref-list></back></article>